Physician profile

Marta Wasiak

Psychiatry · Chico, CA

NPI 1346314291

$397.58

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$141.29

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Sunovion Pharmaceuticals INC. $127.04 2019-2020
Neuronetics, INC. $62.51 2019
Alkermes, INC. $45.49 2023-2024 Lybalvi, Vivitrol
Otsuka America Pharmaceutical, INC. $42.01 2023-2024 Abilify Maintena, Abilify Asimtufii
Abbvie INC. $28.15 2023 Vraylar
Teva Pharmaceuticals USA, INC. $25.64 2023 Uzedy
Takeda Pharmaceuticals U.S.A., INC. $25.07 2019
Lundbeck LLC $24.88 2019
Neos Therapeutics, LP $16.79 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Marta Wasiak

$397.58

in general payments reported 2019-2025

Years
2019-2024
Top company
Sunovion Pharmaceuticals INC.

https://glasscript.com/doctor/288338/marta-wasiak

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.